-
Press ReleaseNovartis announces plans to build flagship manufacturing hub in North Carolina
-
Press ReleaseNew Novartis data at ASN Kidney Week and AHA Scientific Sessions demonstrate momentum of broad CRM portfolio and pipeline
-
Story
Drug delivery, service delivery, and the future of cancer care -
Story
Innovation fueled by compassion -
Story
Shoulder to shoulder -
Press ReleaseNovartis receives FDA approval for Fabhalta® (iptacopan), offering superior hemoglobin improvement in the absence of transfusions as the first oral monotherapy for adults with PNH
-
Press ReleaseNovartis showcases significant data updates from Kisqali®, iptacopan and Scemblix® at SABCS and ASH
-
Story
Treatments for blood cancers and serious blood disorders are advancing rapidly – Novartis is helping lead the way -
Story
A scientist from the start – Q&A with NIBR President Fiona Marshall -
Story
Renewing our commitment to neglected tropical disease and malaria elimination -
Press ReleaseNovartis and Molecular Partners report positive topline data from Phase 2 study for ensovibep (MP0420), a DARPin antiviral therapeutic for COVID-19
-
Press ReleaseNovartis provides an update on Phase III ligelizumab (QGE031) studies in chronic spontaneous urticaria (CSU)